一分钟看懂
这是一项关于非小细胞肺癌的III 期研究，登记的药物或干预包括Nivolumab；Relatlimab；Pembrolizumab；Carboplatin；Pemetrexed；Cisplatin，当前状态为招募中。登记地点显示中国合肥、北京、重庆、万州等城市有研究中心记录。是否仍有名额以及是否值得进一步询问，需要向研究中心确认。
药物或干预
Nivolumab；Relatlimab；Pembrolizumab；Carboplatin；Pemetrexed；Cisplatin · III 期
中国哪些地方有记录
以下地点来自登记信息，不代表此刻仍有名额；请向研究中心确认最新情况。
- Local Institution - 0182 · 合肥
- Beijing Cancer hospital · 北京
- Chongqing University Cancer Hospital · 重庆
- Chongqing Three Gorges Central Hospital · 万州
- Fujian Cancer Hospital · 福州
- The First Affiliated Hospital, Sun Yat-sen University · 广州
- The First Affiliated Hospital of Guangzhou Medical University · 广州
- Huizhou Central People's Hospital · 惠州
- Liuzhou People's Hospital · 柳州
- Guangxi Medical University Affiliated Tumor Hospital · 南宁
- Harbin Medical University Cancer Hospital · 哈尔滨
- The First Affiliated Hospital of Henan Medical University · 新乡
- Local Institution - 0237 · 郑州
- Local Institution - 0235 · 武汉
- Hunan Cancer Hospital · 长沙
- First Huai'an Hospital Affiliated to Nanjing Medical University · 淮安
- The First affiliated hospital of Nanchang University (Xianghu campus) · 南昌
- Liaoning Cancer Hospital · 沈阳
- Xi'an International Medical Center Hospital · 西安
- Shandong Cancer Hospital · 济南
- Shanghai Chest Hospital · 上海
- Zhongshan Hospital,Fudan University · 上海
- Shanxi Cancer Hospital · 太原
- Sichuan Cancer hospital · 成都
- The Second People's Hospital of Neijiang · 内江
- Tianjin Medical University Cancer Institute & Hospital · 天津
- The first Affiliated Hospital, Zhejiang University School of Medicine · 杭州
- Sir Run Run Shaw Hospital of Zhejiang University School of Medicine · 杭州
- Zhejiang Cancer Hospital · 杭州
- Taizhou Hospital of Zhejiang Province · 临海
- Guangdong Provincial People's Hospital · 广州
公开的入选条件
- * Participants must have histologically confirmed Stage IV or recurrent Non-small Cell Lung Cancer (NSCLC) of non-squamous (NSQ) histology with no prior systemic anti-cancer therapy given as primary therapy for advanced or metastatic disease.
- * Participants must have measurable PD-L1 ≥ 1% Tumor Cell (TC) score by the investigational PD-L1 immunohistochemistry (IHC) assay VENTANA PD-L1 (SP263) CDx Assay conducted by central laboratory during the screening period prior to randomization.
- * Participants must have measurable disease by computed tomography (CT) or magnetic resonance imaging (MRI) per RECIST v1.1 criteria.
- * Participants must have an Easter Cooperative Oncology Group (ECOG) performance status of ≤ 1 at screening.
- * Participants must have a life expectancy of at least 3 months at the time of randomization.
- Exclusion Criteria
- * Participants must not be pregnant and/or breastfeeding.
- * Participants with epidermal growth factor receptor (EGFR), anaplastic lymphoma kinase (ALK), or ROS-1 mutations that are sensitive to available targeted inhibitor therapy. Participants with unknown EGFR, ALK, or ROS-1 status are excluded.
联系前需要确认
请继续确认中心是否启动、疾病分型、既往治疗、检查费用和知情同意安排。
查看登记信息
登记号：NCT06561386；登记信息更新于 2026-09-14。